We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
Read MoreHide Full Article
Y-mAbs Therapeutics (YMAB - Free Report) announced that it has completed a pre-biologics license application (pre-BLA) meeting with the FDA for its B7-H3 inhibitor, omburtamab, to treat patients with CNS/leptomeningeal metastases from neuroblastoma.
In the meeting, Y-mAbs Therapeutics discussed the potential pathway for FDA approval of omburtamab. Based on the positive outcome of the meeting, Y-mAbs will be applying for full approval of the drug in the given indication and expects to resubmit the BLA by the end of first-quarter 2022.
Shares of Y-mAbs Therapeutics surged 26% following the news. Yet, the stock has plunged 82.7% in the trailing 12 months in comparison with the industry’s 40.5% decline.
Image Source: Zacks Investment Research
We note that omburtamab has been developed at Memorial Sloan Kettering (MSK) and exclusively licensed to Y-mAbs Therapeutics. The drug is designed to target tumors expressing B7-H3.
Y-mAbs also reported data from the 03-133 clinical study conducted at MSK in 107 evaluable patients with the given indication who were administered up to two doses of radiolabeled omburtamab. While data from the study demonstrated a median survival of 50 months in patients, the final median is yet to be reached. The company plans to report the final data later in 2022 and intends to submit the same in its complete clinical data package to the FDA.
Please note that the company initially submitted the BLA for omburtamab back in August 2020. The FDA issued a Right to Return letter in October 2020 requesting more details with regard to the chemical, manufacturing and control module and clinical module of the BLA.
If approved, omburtamab will be Y-mAbs’ second FDA-approved drug. Currently, the company markets Danyelza (naxitamab-gqgk), which is approved in combination with granulocyte-macrophage colony-stimulating factor, to treat pediatric (1 year and older) and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Danyelza has been developed to target tumors expressing GD2.
Y-mAbs Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the drug/biotech sector include Cara Therapeutics (CARA - Free Report) , Catalyst Pharmaceuticals (CPRX - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) . While Cara Therapeutics currently sports a Zacks Rank #1 (Strong Buy), both Catalyst Pharmaceuticals and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days.
Earnings of Cara Therapeutics beat estimates in three of the last four quarters and missed the mark on one occasion, with the average surprise being126.9%.
Catalyst Pharmaceuticals’ earnings per share estimates for 2022 have increased from 50 cents to 69 cents in the past 30 days. Shares of Catalyst Pharmaceuticals have risen 89.1% in the past year.
Earnings of Catalyst Pharmaceuticals beat estimates in each of the last four quarters, delivering a surprise of 30.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.39 to $14.33 in the past 30 days. The same for 2023 has risen from $14.10 to $15.31 in the past 30 days. VRTX has risen 9.3% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, delivering a surprise of 10%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
Y-mAbs Therapeutics (YMAB - Free Report) announced that it has completed a pre-biologics license application (pre-BLA) meeting with the FDA for its B7-H3 inhibitor, omburtamab, to treat patients with CNS/leptomeningeal metastases from neuroblastoma.
In the meeting, Y-mAbs Therapeutics discussed the potential pathway for FDA approval of omburtamab. Based on the positive outcome of the meeting, Y-mAbs will be applying for full approval of the drug in the given indication and expects to resubmit the BLA by the end of first-quarter 2022.
Shares of Y-mAbs Therapeutics surged 26% following the news. Yet, the stock has plunged 82.7% in the trailing 12 months in comparison with the industry’s 40.5% decline.
We note that omburtamab has been developed at Memorial Sloan Kettering (MSK) and exclusively licensed to Y-mAbs Therapeutics. The drug is designed to target tumors expressing B7-H3.
Y-mAbs also reported data from the 03-133 clinical study conducted at MSK in 107 evaluable patients with the given indication who were administered up to two doses of radiolabeled omburtamab. While data from the study demonstrated a median survival of 50 months in patients, the final median is yet to be reached. The company plans to report the final data later in 2022 and intends to submit the same in its complete clinical data package to the FDA.
Please note that the company initially submitted the BLA for omburtamab back in August 2020. The FDA issued a Right to Return letter in October 2020 requesting more details with regard to the chemical, manufacturing and control module and clinical module of the BLA.
If approved, omburtamab will be Y-mAbs’ second FDA-approved drug. Currently, the company markets Danyelza (naxitamab-gqgk), which is approved in combination with granulocyte-macrophage colony-stimulating factor, to treat pediatric (1 year and older) and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Danyelza has been developed to target tumors expressing GD2.
YmAbs Therapeutics, Inc. Price
YmAbs Therapeutics, Inc. price | YmAbs Therapeutics, Inc. Quote
Zacks Rank & Key Picks
Y-mAbs Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the drug/biotech sector include Cara Therapeutics (CARA - Free Report) , Catalyst Pharmaceuticals (CPRX - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) . While Cara Therapeutics currently sports a Zacks Rank #1 (Strong Buy), both Catalyst Pharmaceuticals and Vertex Pharmaceuticals carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cara Therapeutics’ loss per share estimates for 2022 have narrowed from $1.49 to $1.47 in the past 30 days.
Earnings of Cara Therapeutics beat estimates in three of the last four quarters and missed the mark on one occasion, with the average surprise being126.9%.
Catalyst Pharmaceuticals’ earnings per share estimates for 2022 have increased from 50 cents to 69 cents in the past 30 days. Shares of Catalyst Pharmaceuticals have risen 89.1% in the past year.
Earnings of Catalyst Pharmaceuticals beat estimates in each of the last four quarters, delivering a surprise of 30.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.39 to $14.33 in the past 30 days. The same for 2023 has risen from $14.10 to $15.31 in the past 30 days. VRTX has risen 9.3% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, delivering a surprise of 10%, on average.